Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 15CNS 2Thoracic 1Head & Neck 1

Conditions

Melanoma 2Brain Neoplasms 2Recurrence 1Neoplasms 1Lymphoma 1Central Nervous System Neoplasms 1

Interventions

Radiosurgery 22Nivolumab 21Ipilimumab 19pembrolizumab 15Temozolomide 11dabrafenib 10binimetinib 10encorafenib 8Cyclophosphamide 8trametinib 7Magnetic Resonance Spectroscopy 7Bevacizumab 6fludarabine 5cobimetinib 5Specimen Handling 5CTLA-4 Antigen 5fludarabine phosphate 3aldesleukin 3Vemurafenib 3Thalidomide 3Paclitaxel 3Oxaliplatin 3Interleukin-2 3Gemcitabine 3Drug Therapy 3Carboplatin 3130-nm albumin-bound paclitaxel 3ulixertinib 2tovorafenib 2relatlimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Melanoma × Opdualag × CNS × Clear all
NCT06712927 2026-05-18

Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

Stanford University

Phase 2 Recruiting
60 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

NCT05704933 2026-04-06

Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Completed
1 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡